Patents by Inventor William J. Dower

William J. Dower has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dual IL-2R and IL-7R binding compounds
    Patent number: 11248030
    Abstract: Dual receptor binding compounds comprising IL-2R?, IL-7R?, and R?c ligands, and pharmaceutical compositions comprising the dual receptor binding compounds are disclosed. The dual receptor binding compounds can act as IL-2R and IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: February 15, 2022
    Assignee: MEDIKINE, INC.
    Inventors: William J. Dower, Michael C. Needels, Ronald W. Barrett, Alice V. Bakker, Steven E. Cwirla
  • IL-7R-ALPHA-GAMMA BINDING COMPOUNDS
    Publication number: 20210253670
    Abstract: IL-7R??c binding compounds and pharmaceutical compositions comprising the IL-7R??c binding compounds are disclosed. IL-7R??c bonding compounds can act as IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.
    Type: Application
    Filed: February 3, 2021
    Publication date: August 19, 2021
    Inventors: WILLIAM J. DOWER, MICHAEL C. NEEDELS, RONALD W. BARRETT, ALICE V. BAKKER, STEVEN E. CWIRLA
  • IL-7R-ALPHA BINDING COMPOUNDS
    Publication number: 20210253669
    Abstract: IL-7R? ligands and compounds comprising IL-7R? ligands are disclosed. The IL-7R? binding compounds include fusion proteins comprising the IL-7R? ligands and can act as IL-7R agonists.
    Type: Application
    Filed: February 3, 2021
    Publication date: August 19, 2021
    Inventors: WILLIAM J. DOWER, MICHAEL C. NEEDELS, RONALD W. BARRETT, ALICE V. BAKKER, STEVEN E. CWIRLA
  • IL-2R-BETA-GAMMA BINDING COMPOUNDS
    Publication number: 20210198336
    Abstract: IL-2R??c binding compounds, and pharmaceutical compositions comprising the IL-2R??c binding compounds are disclosed. IL-2R??c binding compounds can act as IL-2R agonists and are useful in treating cancer, autoimmune diseases and inflammatory diseases.
    Type: Application
    Filed: November 4, 2020
    Publication date: July 1, 2021
    Inventors: WILLIAM J. DOWER, MICHAEL C. NEEDELS, RONALD W. BARRETT, ALICE V. BAKKER, STEVEN E. CWIRLA
  • DUAL IL-2R AND IL-7R BINDING COMPOUNDS
    Publication number: 20210130424
    Abstract: Dual receptor binding compounds comprising IL-2R?, IL-7R?, and R?c ligands, and pharmaceutical compositions comprising the dual receptor binding compounds are disclosed. The dual receptor binding compounds can act as IL-2R and IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.
    Type: Application
    Filed: November 4, 2020
    Publication date: May 6, 2021
    Inventors: WILLIAM J. DOWER, MICHAEL C. NEEDELS, RONALD W. BARRETT, ALICE V. BAKKER, STEVEN E. CWIRLA
  • MODIFIED T CELL RECEPTORS
    Publication number: 20210115106
    Abstract: Provided herein are modified T cell receptors (TCRs), pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same. The modified TCRs described herein are modified with a peptide.
    Type: Application
    Filed: December 6, 2018
    Publication date: April 22, 2021
    Inventors: David CAMPBELL, Ramesh BHATT, Thomas R. DIRAIMONDO, Steven E. CWIRLA, Blake M. WILLIAMS, Praechompoo PONGTORNPIPAT, William J. DOWER
  • IL-2ALPHA RECEPTOR SUBUNIT BINDING COMPOUNDS
    Publication number: 20200399314
    Abstract: Peptidyl IL-2R? ligands and compounds comprising the IL-2R? ligands are disclosed. The IL-2R? ligands and compounds such as synthetic monomers, homodimers, or heteromers and recombinant fusion proteins comprising the IL-2R? ligands can be used as targeting or imaging agents, as diagnostics or to treat cancers and autoimmune diseases.
    Type: Application
    Filed: June 2, 2020
    Publication date: December 24, 2020
    Inventors: WILLIAM J. DOWER, MICHAEL C. NEEDELS, RONALD W. BARRETT, ALICE V. BAKKER, STEVEN E. CWIRLA
  • MODIFIED BISPECIFIC T CELL RECEPTORS
    Publication number: 20200385440
    Abstract: Provided herein are modified T cell receptors (TCRs), pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same. The modified TCRs described herein are modified with a peptide.
    Type: Application
    Filed: December 6, 2018
    Publication date: December 10, 2020
    Inventors: David CAMPBELL, Ramesh BHATT, Thomas R. DIRAIMONDO, Steven E. CWIRLA, Blake M. WILLIAMS, Praechompoo PONGTORNPIPAT, William J. DOWER
  • IL-2RGAMMA BINDING COMPOUNDS
    Publication number: 20200291067
    Abstract: IL-2R? ligands and IL-2R?c ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2R? ligands and/or the IL-2R?c ligands can be IL-2 receptor agonists.
    Type: Application
    Filed: May 27, 2020
    Publication date: September 17, 2020
    Applicant: MEDIKINE, INC.
    Inventors: WILLIAM J. DOWER, MICHAEL C. NEEDELS, RONALD W. BARRETT, ALICE V. BAKKER, STEVEN E. CWIRLA
  • IL-2RBETA BINDING COMPOUNDS
    Publication number: 20200291066
    Abstract: IL-2R? ligands and IL-2R?c ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2R? ligands and/or the IL-2R?c ligands can be IL-2 receptor agonists.
    Type: Application
    Filed: May 27, 2020
    Publication date: September 17, 2020
    Applicant: MEDIKINE, INC.
    Inventors: WILLIAM J. DOWER, MICHAEL C. NEEDELS, RONALD W. BARRETT, ALICE V. BAKKER, STEVEN E. CWIRLA
  • IL-2RBeta binding compounds
    Patent number: 10703776
    Abstract: IL-2R? ligands and IL-2R?c ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2R? ligands and/or the IL-2R?c ligands can be IL-2 receptor agonists.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: July 7, 2020
    Assignee: MEDIKINE, INC.
    Inventors: William J. Dower, Michael C. Needels, Ronald W. Barrett, Alice V. Bakker, Steven E. Cwirla
  • IL-2R? binding compounds
    Patent number: 10689417
    Abstract: IL-2R? ligands and IL-2R?c ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2R? ligands and/or the IL-2R?c ligands can be IL-2 receptor agonists.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: June 23, 2020
    Assignee: MEDIKINE, INC.
    Inventors: William J. Dower, Michael C. Needels, Ronald W. Barrett, Alice V. Bakker, Steven E. Cwirla
  • IL-2RGAMMA BINDING COMPOUNDS
    Publication number: 20200040036
    Abstract: IL-2R? ligands and IL-2R?c ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2R? ligands and/or the IL-2R?c ligands can be IL-2 receptor agonists.
    Type: Application
    Filed: August 5, 2019
    Publication date: February 6, 2020
    Applicant: MEDIKINE, INC.
    Inventors: William J. Dower, Michael C. Needels, Ronald W. Barrett, Alice V. Bakker, Steven E. Cwirla
  • IL-2RBETA BINDING COMPOUNDS
    Publication number: 20200040034
    Abstract: IL-2R? ligands and IL-2R?c ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2R? ligands and/or the IL-2R?c ligands can be IL-2 receptor agonists.
    Type: Application
    Filed: August 5, 2019
    Publication date: February 6, 2020
    Applicant: MEDIKINE, INC.
    Inventors: WILLIAM J. DOWER, MICHAEL C. NEEDELS, RONALD W. BARRETT, ALICE V. BAKKER, STEVEN E. CWIRLA
  • MODIFIED ANTIBODIES
    Publication number: 20180339043
    Abstract: Provided herein are modified antibodies, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same. The modified antibodies described herein are modified with a peptide. The peptide binds at or near the antigen binding site of the antibody at physiological pH, thus reducing binding affinity of the antibody for a target antigen. At acidic pH, the binding interaction of the peptide at or near the antigen binding site is disrupted, thus enabling binding with a target antigen.
    Type: Application
    Filed: May 24, 2018
    Publication date: November 29, 2018
    Inventors: David Campbell, Ramesh Bhatt, William J. Dower, Steven E. Cwirla, Blake M. Williams
  • NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR
    Publication number: 20130012685
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: July 3, 2012
    Publication date: January 10, 2013
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, Yaohua S. Dong, David Tumelty, Guy Lalonde, Brian T. Frederick, Anjan Chakrabarti, Palani Balu, Peter J. Schatz, Nicholas C. Wrighton, William J. Dower
  • Peptides and compounds that bind to a receptor
    Patent number: 8227422
    Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: July 24, 2012
    Assignee: Glaxosmithkline LLC
    Inventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, David J. Duffin, Christian M. Gates, Sherril S. Haselden, Larry C. Mattheakis, Peter J. Schatz, Christopher R. Wagstrom, Nicholas C. Wrighton
  • NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR
    Publication number: 20120157660
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: August 18, 2010
    Publication date: June 21, 2012
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, David Tumelty, Guy Lalonde, Palani Balu, Peter J. Schatz, William J. Dower, Anjan Chakrabarti, Yaohua S. Dong, Brian T. Frederick, Nicholas C. Wrighton
  • Creatine phosphate analog prodrugs, compositions and uses thereof
    Patent number: 8202852
    Abstract: Membrane permeable prodrugs of creatine phosphate analogs, pharmaceutical compositions comprising membrane permeable prodrugs of creatine phosphate analogs, and methods of treating diseases such as ischemia, heart failure, and neurodegenerative disorders comprising administering prodrugs of creatine phosphate analogs, or pharmaceutical compositions thereof are disclosed.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: June 19, 2012
    Assignee: XenoPort, Inc.
    Inventors: Noa Zerangue, Qingzhi Gao, William J. Dower
  • NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR
    Publication number: 20110282029
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: December 10, 2010
    Publication date: November 17, 2011
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, Yaohua S. Dong, David Tumelty, Guy Lalonde, Brian T. Frederick, Anjan Chakrabarti, Palani Balu, Peter J. Schatz, Nicholas C. Wrighton, William J. Dower